Can a single drug preserve sight in rare retinal diseases? new study aims to find out.
NCT ID NCT07348588
First seen Jan 23, 2026 · Last updated May 23, 2026 · Updated 23 times
Summary
This study tests whether injecting adalimumab (an anti-inflammatory drug) directly into the eye can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty adults will receive three injections over four months, and researchers will measure changes in visual field and sharpness after six months. The goal is to see if the treatment is safe and can slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA (RP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rubens Siqueira Research Center
São José do Rio Preto, São Paulo, 15010-100, Brazil
Conditions
Explore the condition pages connected to this study.